https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44505 Wed 16 Aug 2023 09:41:09 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12931 Wed 11 Apr 2018 17:11:41 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26675 Wed 11 Apr 2018 14:02:29 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5107 Wed 11 Apr 2018 13:35:26 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36853 Tue 14 Jul 2020 13:56:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:412 = 6.6 v <= 5.0 mmol/L 1.27 (1.06-1.53); and not ever having had a raised cholesterol 1.20 (1.04-1.40). There was no difference in cardiovascular disease end points and death in those who were and were not initiated on drug therapy at randomization. Conclusions: Failure to initiate antihypertensive therapy for patients at the randomization visit was associated with lower BP measurements, previous drug therapy, younger age, and a historic or current raised cholesterol, but not with overt cardiovascular disease or other risk factors. There was no difference in cardiovascular disease end points and death in those who were and were not initiated on drug therapy at randomization.]]> Thu 25 Jul 2013 09:09:51 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31895 Mon 23 Sep 2019 13:18:04 AEST ]]>